China Pharma acquires COPD drug patent for $1.65M in restricted stock; royalty of 15% net profit

CHINA PHARMA HOLDINGS, INC.

Subsidiary Helpson enters Technology Transfer Agreement with Tao Liu for a COPD drug combination patent.
Consideration: 15,000,000 restricted shares at $0.11/share ($1.65M) under Regulation S exemption.
Helpson to pay 15% of net profit from product sales annually for 10 years if product is profitable.
Transferor to provide R&D, registration, and technical services in Haikou.
Shares are unregistered and issued in an offshore transaction to a non-U.S. person.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Tao Liu valued at $1.65 million (effective 2023-12-15).

Action: entry
Counterparty: Tao Liu
Value: $1.65 million
Effective: 2023-12-15

Exact text from the filing

On December 15, 2023, Hainan Helpson Medical & Biotechnology Co., Ltd (“ Helpson ”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “ Company ”), entered into a Technology Transfer Agreement (the “ Agreement ”) with Tao Liu (the “ Transferor ”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

CHINA PHARMA HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-097680

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.